Application of fibrinogen concentrate (Fibrinogen HT) to uncontrollable massive bleeding

Application of fibrinogen concentrate (Fibrinogen HT) to uncontrollable massive bleeding - Application of Fibrinogen HT to massive bleeding

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022666

Enrollment

Registered

2016-06-08

Start date

2016-06-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Massive bleeding during 1)Pregnancy and delivery 2)Cardiovascular surgery 3)Gastrointestinal (including hepato-biliary-pancreatic) surgery

Interventions

Intravenous administration of Fibrinogen HT(3g) in ten minuites to uncontrollable massive bleeding whose fibrinogen value is under 100mg/dl. Historical controls are number of patients under same condi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Massive bleeding during pregnancy or delivery, increased bleeding (>4000ml) during cardiovascular surgery, or gastrointestinal (including hepato-biliary-pnacreatic) surgery whose fibrinogen value is lower than 100mg/dl or suspected to be lower than 100mg/dl in case of emergency.

Exclusion criteria

Exclusion criteria: Patient (or the patient's family) who did not give informed consent.

Design outcomes

Primary

Measure	Time frame
Avoidance rate of using fresh allogenic blood obtained in the hospital to uncontrollable massive bleeding	—

Secondary

Measure	Time frame
Survival rate Fibrinogen value before and after the usage of fibrinogen concentrate Blood loss Blood product usage	—

Countries

Japan

Contacts

Public ContactYoshitaka Furukawa

Kagoshima University Hospital Division of blood transfusion medicine and cell therapy

furukawy@m2.kufm.kagoshima-u.ac.jp099-275-5635

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026